Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.
Figlin says checkpoint inhibitors and next generation single-agent or combination TKIs may be the future of treatment. He adds that while currently sequences of drugs have prolonged survival for kidney cancer patients, it still means patients are receiving drugs for an elongated period of time. Figlin says that he hopes upcoming novel approaches to treating kidney cancer could mean better treatment for patients with less toxicities.
In a recent study published byThe New England Journal of Medicine, patients with advanced renal cell carcinoma had an improved overall survival rate of 5.4 months while on nivolumab (Opdivo) versus everolimus (Afinitor).